Physician profile
Joseph A Huschart
NPI 1003818402
$4,161.38
in general payments reported to CMS, 2019-2025
24 companies · $754 in 2025
The $754 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $216 · 2021: $364 · 2022: $909 · 2023: $688 · 2024: $889 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,338.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $431.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $391.97 | 2019-2025 | |
| Abbott Laboratories | $247.31 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.99 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Xeris Pharmaceuticals, INC. | $228.61 | 2022-2024 | Gvoke Hypopen |
| Abbvie INC. | $227.61 | 2022-2025 | |
| Exact Sciences Corporation | $219.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $107.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $103.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $103.21 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.89 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $64.78 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $59.85 | 2025 | Austedo Xr |
| Astellas Pharma US INC | $55.69 | 2019-2023 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.78 | 2022-2025 | Farxiga |
| Avanir Pharmaceuticals, INC. | $43.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.49 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $26.76 | 2022-2023 | Belsomra, Steglatro |
| Sequel Med Tech, LLC | $26.25 | 2025 | Twiist |
| Medtronic, INC. | $22.49 | 2021 | |
| Axsome Therapeutics, INC. | $15.71 | 2025 | Auvelity |
| Amgen INC. | $15.60 | 2019 | |
| Ucb, INC. | $14.65 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Huschart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.